Session » (1412–1441) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II: SpA

Date: Monday, November 13, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM: Abstract Number: 1430

A Proof-of-concept Study Evaluating the Use of Functional Brain Magnetic Resonance Imaging in Assessing Treatment Response in Psoriatic Arthritis Patients

9:00AM-11:00AM: Abstract Number: 1439

Better Drug Retention on anti-IL17A Compared to Anti-TNF Therapy Despite Its Inferior Effect on Composite Joint Indexes and Quality of Life in Patients with PsA–analysis from the Czech Biologics Registry ATTRA

9:00AM-11:00AM: Abstract Number: 1433

Bimekizumab Impact on Core Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Domains for Patients with Psoriatic Arthritis: 52-Week Results from Four Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 1437

Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naïve Patients with Psoriatic Arthritis Who Were Responders at Week 16: Results from a Phase 3, Active-Reference Study

9:00AM-11:00AM: Abstract Number: 1441

Bimekizumab Maintenance of Response and Safety in Patients with Moderate to Severe Plaque Psoriasis: Results from the Open-label Extension Period (Weeks 48–144) of the BE RADIANT Phase 3b Trial

9:00AM-11:00AM: Abstract Number: 1415

Bimekizumab Treatment Impact on Work Productivity in Biologic DMARD‑Naïve and TNFi-IR Patients with Active Psoriatic Arthritis: Results up to 1 Year from Two Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 1420

Changes in Serum Cytokines and Collagen Proteins Correlate with Durability of Guselkumab Efficacy and Continued Disease Improvement Through 2 Years in Patients with Active Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1426

Distinct Treatment Response Trajectories in Patients with Psoriatic Arthritis Receiving Tofacitinib

9:00AM-11:00AM: Abstract Number: 1417

Do Long-term Patient-reported Outcomes Improve Similarly in Psoriatic Arthritis and Axial Spondyloarthritis Patients Treated with Secukinumab? Results from the EuroSpA Collaboration

9:00AM-11:00AM: Abstract Number: 1421

Domains Impacting Minimal Disease Activity Non-Achievement in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors Receiving Guselkumab (COSMOS)

9:00AM-11:00AM: Abstract Number: 1424

Early Fatigue Improvement with Guselkumab Associates with Longer Term Disease Control in Patients with Active Psoriatic Arthritis Reporting Substantial Fatigue: Post Hoc Analyses of a Sub-Population of a Phase 3, Randomized, Controlled Trial of Guselkumab in Biologic-Naïve Patients

9:00AM-11:00AM: Abstract Number: 1413

Effect of Apremilast Treatment on the Domains of MDA-Joints in Patients with Early Oligoarticular Psoriatic Arthritis: 16-Week Results from FOREMOST

9:00AM-11:00AM: Abstract Number: 1414

Effects of Apremilast on Changes in Cardiometabolic Parameters by Diabetes and Obesity Status in Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1425

Efficacy and Safety of Tofacitinib in an Open-Label, Long-Term Extension Study in Patients with Psoriatic Arthritis Who Received Adalimumab or Tofacitinib in a Phase 3 Randomized Controlled Study: A Post Hoc Analysis

9:00AM-11:00AM: Abstract Number: 1438

Efficacy of Guselkumab in Early-Onset and Late-Onset Psoriatic Arthritis: Post Hoc Pooled Analyses of Two Phase 3 Randomized Controlled Trials in Patients with Active PsA

9:00AM-11:00AM: Abstract Number: 1418

Efficacy of the Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, on Psoriasis in Patients with Active PsA: Results from a Phase 2 Trial

9:00AM-11:00AM: Abstract Number: 1427

Efficacy of Upadacitinib in Patients with Psoriatic Arthritis Stratified by Involvement of Weight-bearing Joint Regions: A Post Hoc Subgroup Analysis of the Phase 3, Randomized, SELECT-PsA 1 and SELECT-PsA 2 Trials

9:00AM-11:00AM: Abstract Number: 1432

Experiences and Perspectives of Patients with Psoriatic Arthritis Participating in a Randomized Controlled Trial of Dietary Interventions

9:00AM-11:00AM: Abstract Number: 1428

Guselkumab Provides Clinically Meaningful Improvents in Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis Who Are Inadequate Responders to Tumour Necrosis Factor Inhibitors: Results Through One Year of a Phase 3b, Randomized, Controlled Study (COSMOS)

9:00AM-11:00AM: Abstract Number: 1419

Impact of Psoriatic Arthritis Manifestations on Perception of Pain Improvement: Pooled Analysis of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies with Guselkumab

9:00AM-11:00AM: Abstract Number: 1423

Impact of Upadacitinib on Enthesitis and Dactylitis by Location in Patients with Psoriatic Arthritis and an Inadequate Response to Biologic DMARDs from the SELECT-PsA 2 Trial

9:00AM-11:00AM: Abstract Number: 1416

Improvement of Work Absenteeism Following Start of Methotrexate Monotherapy in Newly-Diagnosed Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1412

Improvements in Patient-Reported Outcomes Through 6 Months of Guselkumab Treatment in Patients with Active Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

9:00AM-11:00AM: Abstract Number: 1431

Izokibep, a Unique IL-17A Inhibitor, Improves Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis up to Week 46 – Phase 2 RCT Results

9:00AM-11:00AM: Abstract Number: 1434

Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 148-Week Results from the KEEPsAKE 2 Trial

9:00AM-11:00AM: Abstract Number: 1435

Long-Term Efficacy and Safety of Risankizumab for CsDMARD-IR Patients with Active Psoriatic Arthritis: 148-Week Results from the KEEPsAKE 1 Trial

9:00AM-11:00AM: Abstract Number: 1422

Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: Integrated Analysis of Psoriasis and Psoriatic Arthritis Clinical Trial Data

9:00AM-11:00AM: Abstract Number: 1429

Longitudinal Evaluation of the Novel Psoriatic Arthritis 5-Thermometer Scale (PsA-5Ts) Domains During Treatment with Guselkumab: Pooled Analysis of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies

9:00AM-11:00AM: Abstract Number: 1440

Removal of Methotrexate in Patients with Active Psoriatic Arthritis with Newly Induced Ustekinumab Treatment Leads to a Delayed Response in DAPSA and DAS28 Within the First 16 Weeks

9:00AM-11:00AM: Abstract Number: 1436

Secukinumab Demonstrates a Consistent Safety Profile in Patients with Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis: Updated Pooled Safety Analysis from Clinical Trials

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].